ArticleJournal of feline medicine and surgery2026
Efficacy of mesenchymal stem cell therapy for treating deep corneal ulcers and corneal perforation in cats: a retrospective study.
Article in Journal of feline medicine and surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivesThis study evaluated the therapeutic effects of subconjunctival injection of mesenchymal stem cells (MSCs) for treating deep corneal ulcers and corneal perforation in cats.MethodsOf the 24 cats identified with a deep corneal ulcer or perforation, 17 received MSCs and medical treatment; among them, six had deep corneal ulcers and 11 had corneal perforations. Of the seven cats that received only medical treatment, three cats had deep corneal ulcers and four cats had corneal perforations. All were monitored with fluorescein staining at 3-4 days and weekly assessments after MSC injection until fluorescein-negative status was achieved.ResultsOutcomes were compared between cats treated with subconjunctival MSC injections and MSC-untreated cats. Based on the results, 15/17 (88%) cats treated with MSCs became fluorescein-negative within 1-3 weeks, whereas 2/17 (12%) of those receiving subconjunctival MSC injections achieved this outcome within 5-6 weeks. During the mean follow-up period of 146 ± 138 days (range 15-398) after MSC injection, recurrence of corneal perforations was observed in four cats that were ultimately completely healed. All deep corneal ulcers healed uneventfully. In the MSC-untreated group, 4/7 (57%) achieved fluorescein-negative status within 3-7 weeks, while another 2/7 (29%) experienced recurrent corneal perforation on days 3 and 58, requiring conjunctival graft surgery. Postoperatively, fluorescein-negative status was achieved 25 and 72 days after the initial treatment, respectively. Of the seven cats, one (14%) had recurrent corneal perforation that had healed on day 103.Conclusions and relevanceThese findings highlight the potential of MSC therapy in promoting corneal ulcer and corneal perforation healing in cats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.